News
Events
36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Barcelona, Spain)
Bio Investment Convention
Under the dynamic leadership of Bridge 2 Health (B2H), the BIO Investment Convention represents a unique opportunity in Wallonia. This ambitious event aims to support the growth of Walloon life sciences companies, bringing together the national and international networks of eleven key partners. As a result, the BIC stands as a premier gathering of leading investors, hubs and 12 biotech scale-ups, each offering innovative technology and specialized expertise. Additionally, it brings together 200 representatives from industry, funding
organizations, consulting, services, and public authorities.
American Association for Cancer Research
Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors : Preventing deleterious ‘de-hinging’ to improve tolerability.
Press Releases
DeuterOncology obtains SPW grant funding
DeuterOncology, a Liège-Based (BE) biotech company, is pleased to announce it has successfully been awarded the Win4Company grant by the Wallonie recherche SPW. The clinical-stage drug development company has been granted 478,000 EUR for establishing a partnership with a Liège-based biotech, Radiomics, for the development and validation of an AI-based imaging biomarker as a potential companion diagnostic for a novel best-in-class deuterated MET kinase inhibitor (DO-2) as an optimized personalized cancer therapy.
DeuterOncology closes €5.65M Series A financing round
DeuterOncology, a clinical-stage drug development company, today announces the closing of its €5.65 million ($6.1M) Series A financing, with participation from historical investor Newton Biocapital and new investors Noshaq and Investsud Tech.
This funding will enable the company to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer.
Newton Biocapital invests in Flemish start-up DeuterOncology
Newton Biocapital I (“Newton Biocapital”), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced investment in DeuterOncology. Newton Biocapital’s second investment in Flanders.
DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapy.
Els Hubloux, partner at Newton Biocapital Partners: “DeuterOncology brings a wealth of experience in pre-clinical and clinical research, for kinase inhibitors in general and particularly for MET inhibitors. Newton Biocapital is proud to take DeuterOncology into its portfolio, with the ambition to bring novel treatment approaches for cancer patients closer to market.”
